GlassScriptPhysician profile
Michael G O'Rourke
NPI 1851742332
$4,602.55
in general payments reported to CMS, 2019-2025
24 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $785 · 2023: $2,848 · 2024: $495 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063 · Travel and Lodging: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.43 |
| Travel and Lodging | $1,381.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,140.72 | 2021-2023 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $598.52 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $433.60 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $326.34 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $180.32 | 2021-2023 | |
| Antares Pharma, INC. | $115.14 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Insulet Corporation | $103.11 | 2022-2023 | Omnipod |
| Tandem Diabetes Care, INC. | $71.90 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $71.01 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.51 | 2022-2023 | Jardiance |
| Mannkind Corporation | $64.83 | 2023-2024 | Afrezza |
| Penumbra, INC. | $62.79 | 2025 | Indigo System |
| Abbvie INC. | $59.78 | 2023-2024 | |
| Halozyme INC | $44.01 | 2023 | |
| Merck Sharp & Dohme LLC | $41.99 | 2023 | Steglatro, Belsomra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $39.63 | 2025 | |
| Tolmar, INC. | $39.26 | 2024 | |
| Ibsa Pharma INC. | $32.85 | 2022-2024 | Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $24.50 | 2023 | Unithroid |
| Recordati_rare_diseases_inc. | $22.17 | 2024 | Signifor Lar, Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $17.43 | 2022 | |
| Amgen INC. | $15.08 | 2021 | |
| Embecta Corp. | $14.34 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Astrazeneca Pharmaceuticals LP | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael O'Rourke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.